Annual Shareholders’ Meeting

October 29, 2015

Disclaimer Cautionary Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, benefits of investments and partnerships, business strategies and other matters. Such statements can be identified by words such as: “expected,” “expects,” “expect,” “forecast,” “would,” “estimate,” “will,” or similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see our latest Annual Report on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise. This presentation also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For definitions of applicable non-GAAP financial measures and reconciliations of non-GAAP financial information to GAAP financial information, see the Reconciliations of GAAP to Non-GAAP Financial Measures included in the Company’s financial reports on Forms 10-Q and 10-K and related press releases.

2

Introductions

Business Meeting

Business Overview

Financial Report

Questions and Answers

Recognition of Howard O’Connell

Agenda

3

4

Corporate Leadership Team

Dr. Fernando Bazan Chief Technology

Officer

Gerry Andros Vice President

Sales

Peter Breloer Vice President

Asia Pacific

Ruth Bright Managing Director

R&D Systems Europe

5

Corporate Leadership Team

Brenda Furlow Senior Vice President and General Counsel

Dave Eansor Sr. Vice President Biotech Division

Bob Gavin Senior Vice President

Protein Platforms

Kevin Gould Vice President

Cliniqa

Dr. Frank Mortari Vice President

Corporate Development

6

Corporate Leadership Team

Jim Hippel Chief Financial

Officer

Dr. Ruyi Hao Vice President and Corporate Scientist

Dave LePage Chief Information

Officer

7

Corporate Leadership Team

Dr. Dave Peters Managing Director

Tocris

Dr. Kevin Reagan Vice President

Operations and Product Development

Struan Robertson Vice President

Human Resources

Karen Padgett Vice President

Marketing

8

Corporate Leadership Team

Marcel Veronneau Senior Vice President

Clinical Controls

Dr. Wendy Shao Managing Director

R&D Systems China

Dr. Diane Wotta Senior Director

Quality and Regulatory Affairs

9

Bio-Techne Board Members

Robert Baumgartner, Chairman Dr. Roger Lucas, Vice Chair Dr. Charles Dinarello John Higgins Dr. Karen Holbrook Dr. Roeland Nusse Howard O’Connell Dr. Randolph Steer Harold Wiens

Meeting Called to Order

Proxy Results

Motion to Adjourn

Business Meeting

10

11

Strategic Plan Update

Chuck Kummeth

Global footprint • Minneapolis, MN, based • 1400+ employees worldwide • Offices in North America, Europe and China

Leadership position in cytokine/growth factors, immunoassays and small molecules

Deep product portfolio and applications expertise

Provider of biological reagents and instruments for a variety of life science applications

One of three manufacturers of clinical blood controls

Key recent acquisitions and investments: ProteinSimple, Novus, PrimeGene, Bionostics, Cyvek and Cliniqa

Fiscal Year Ends: June 30

FY 2015 Revenues: $452M

FY 2015 Gross Margin: 71.4%

FY 2015 Adj. Earnings: $127M

FY 2015 Adjusted EPS: $3.40

Current Market Cap: $3.6B

12

Current Business Overview

13

Bio-Techne Mission

To provide the Life Sciences community with innovative, high-quality, scientific tools to better

understand biological processes and drive discovery

Building on the Techne Legacy • Targeted acquisitions to build on the legacy

brands and expand our product portfolio in specified markets

• Build on our leadership position in Proteins and Assays to a recognized leader in Antibodies and Multiplex solutions

• Recognized leader in quality and delivery of biological content to both industrial and academic customers globally

• Expansion of our Clinical Controls capabilities and products

Attractive Financial Returns • Revenues $1B

• Organic revenue CAGR 10%

• Including Acquisitions: EBITDA 40%

• Re-investment in R&D = 9-10% of Revenues

• 28% of sales in Asia-Pacific vs. 14%

• Margin decrease acceptable in exchange for accelerated revenue growth

Goal To be recognized globally for providing quality biological content and leverage this strength to enter diagnostic and adjacent markets

Strategy Leverage our deep product development and manufacturing capabilities to deliver innovative, disruptive and more complete solutions for the markets we serve utilizing our industry-leading channels and gap-filling acquisitions to address customers’ life science research and diagnostic needs

Achievement of annual revenues in excess of $1B within five years and demonstrate improvement in the vitality index (NPVI of >10% of sales from products introduced in last three years)

Success

14

Strategic Plan Summary (2014 – 2019)

Branding Strategy

15

SIMPLE PLEX

Core Products and Innovation

Geographic Expansion

Commercial Execution

Operational Excellence

Talent Recruitment

and Retention

• First to market quality products at the leading edge of researchers’ needs

• Continued investment of 9-10% of revenues into research activities

• Leverage strong balance sheet - gain access to new technologies to deploy our content

• Drive collaborations through Key Opinion Leaders (KOLs)

• Continued expansion of sales force in China

• Opening of sales office in Beijing

• Low-cost China manufacturing capabilities

• Expansion in Latin America

• Expand new Protein Platforms division in Europe and China

• Local sales staff in key US regional hubs

• SEA distribution managed locally

• Investment in key tools and instruments that drive additional consumables revenue

• Expand distribution channels through Fisher and VWR agreements

• Leverage large ProteinSimple sales force

• Creating a manufacturing organization to extract efficiencies in production

• Realignment of reporting groups within Bio-Techne to create more efficient operations

• Introduce new Business and ERP systems to company

• Key management hiring (Divisions SVP, CTO, VP Sales, VP Marketing, VP HR, VP Asia Pacific, Finance Directors, etc.)

• Implement compensation structures to attract and retain top talent

• Expansion and retention in Asia

• Staffing of legal office

• Addition of new talent through acquisitions

Strategy Summary

16

17

Core Reagents Clinical Controls and IVD

Cell-Based Controls Proteins Antibodies Assays Small Molecules

Protein Platforms

Low-cost protein manufacturing in

China

~250,000 additional Abs and digital

platform

Immunoassay automation and

multiplexing

Blood chemistry, blood and IVD

controls

SIMPLE PLEX

Products and Technology Expansion

Targets with ROIC > WACC

Targets that fill perceived gaps

Sound prioritization strategy

Healthy hopper of targets

M&A Strategy

18

Closed PrimeGene – April 2014 Closed Novus and ProteinSimple – July 2014

Closed CyVek – November 2014 Closed Cliniqa – July 2015

Number of Bio-Techne Sites: 21 Integration of Novus into Bio-Techne Operations

Integration of CyVek into ProteinSimple

Significant Achievements in Last Two Years

19

Allen Pierce – Vice President Operations, ProteinSimple Dave Eansor – Sr. Vice President, Biotech

Ellen Scipta – Sr. Director of Finance Gerry Andros – America and Europe Commercial

Karen Padgett – Vice President, Marketing Kason Klumpyan – Corporate Controller

Kevin Gould – Vice President, Cliniqa Peter Breloer – Vice President, Asia Pacific

Struan Robertson – Vice President, Human Resources

Significant Achievements in Last Two Years

20

Tocris New Building New Website and Chat Line

New ERP and Hyperian Systems Financial Consolidation Processes

Employee Count 1400+ First Leadership Development Training

Replacing All Computers – 54% Complete United Way Donation $50K+

Operations Efficiencies $2MM

Significant Achievements in Last Two Years

21

1684 New Products in 2015 = $5.8MM FY15 Revenue Growth 3.6%

FY15 Adjusted EBITDA growth 9.0% China achieves >$25MM sales

Fisher sales exceed $35MM NA Academic sales get back to positive territory

Patent Committee meetings resulting in patent filings Solid Investor Relations program with >100 meetings

Significant Achievements in Last Two Years

22

Community Affairs

23

Financial Report

Jim Hippel, CFO

24

Financial Trends

Organic Sales Growth1 2% 6% 2% 0% 3% 4%

1Organic sales exclude the impact of acquisitions and foreign currency exchange rates

25

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

$0

$50

$100

$150

$200

$250

$300

$350

$400

$450

$500

FY10 FY11 FY12 FY13 FY14 FY15

Revenue ($Mil)

EBITDA ($Mil)

EBITDA Margin (%)

TECH vs. S&P 500

Share Performance vs. Market

Overall, historical stock price performance has out-performed S&P500 26

~ 72% of Sales High 70s Gross Margin%

Low 50s Op. Margin%

~ 15% of Sales High 60s Gross Margin%

High single-digit Op. Margin%

~ 13% of Sales Mid 40s Gross Margin% Low 30s Op. Margin%

• R&D Systems • Tocris • Boston Biochem • BiosPacific • PrimeGene • Novus

Clinical Controls

Biotechnology

FY 2015 Reportable Segments

Protein Platforms • ProteinSimple • CyVek

27

CCD Minneapolis CCD Devens Cliniqa (beg. FY16)

USA Europe China Pacific Rim ROW

53%

24%

10% 6% 7%

FY 2015 Biotech Segment Sales by Geography

+3% growth

flat growth

+24% growth

(2%) growth

28

Solid organic growth in core businesses: Margins impacted by acquisitions, EPS impacted by FX headwinds

29

Fiscal Year 2015 Financial Highlights

($MM)

Organic growth impacted by OEM shipment timing; Margins and EPS impacted by acquisitions

30

Q1 FY16 Financial Highlights

($MM)

The brands under the Bio-Techne name have a strong, global

recognition built on the reputation of being long term quality reagents

suppliers. As we have acquired additional strong brands and

technologies they have allowed us to re-defined ourselves for our

customers and offer them an extended product portfolio that

accommodated more of their needs. As a more complete solution

solutions provider to our loyal customers we believe we can derive

greater economic and see our products transition from the research

bench to the clinical lab. These are some of the changes we are

implementing at Bio-Techne to drive long term growth. 31

Conclusion

31

Questions & Answers

32 32

Howard O’Connell

In Appreciation of 35 years of

Distinguished Service

33 33

Bio-Techne Board Retirement

THANK YOU!

34 34